We are developing CMD-004, which consists of antigen-specific T cells that target the human papilloma virus (HPV).

Eligible patient population

HPV is an extremely common viral infection and is associated with 70% to 90%1 of cervical, oropharyngeal and anogenital cancers.

Despite recent advances in vaccination treatments, cervical cancer still presents a major health risk and each year around 528,0002 new cases are diagnosed and 266,0002 deaths occur globally. Patients with early stage cervical cancer may be successfully treated with a simple surgical procedure, however later stage patients require chemo or targeted antibody therapy and generally have a poorer prognosis.

Oropharyngeal and anogenital cancers are also strongly associated with HPV. Around 12,000 patients in the US3 and 20,000 in the EU are diagnosed annually with HPV-related oropharyngeal cancer. HPV-related anogenital cancer is less frequent, but still affects around 13,000 patients every year in the US and EU combined3.

The development of CMD-004

CMD-004 is in the preclinical stages of development and has the potential to effectively treat cervical, oropharyngeal and anogenital cancer patients.